ClinicalTrials.gg
CompletedNCT01438840Updated Feb 5, 2018Results posted

Efficacy and Safety of Oral E5501 Plus Standard of Care for the Treatment of Thrombocytopenia in Adults With Chronic Immune Thrombocytopenia (Amendment 02)

A Phase 3 interventional study of Avatrombopag and Placebo in Chronic Thrombocytopenia and Immune Thrombocytopenia, sponsored by Eisai Inc.. Completed at 25 sites in 11 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-02-05.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
49
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
10th of 16
49 · median 53
Started
2012
with 1 other
Phase 3
6 of 16
1 open now
Registered
6th of 16
by date
Lead sponsor
7 of 16
Eisai Inc.

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 10th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 3, and was the 6th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

Core Study:

To demonstrate that the efficacy of avatrombopag (in addition to standard of care) is superior to placebo (in addition to standard of care) for the treatment of adult participants with chronic immune thrombocytopenia (idiopathic thrombocytopenic purpura) (ITP) as measured by cumulative number of weeks of platelet response over 6 months of once daily treatment in adults participants who received at least 1 prior ITP therapy.

Extension Phase:

To evaluate the safety and tolerability of long-term therapy with avatrombopag in participants with chronic ITP (cITP).

Read the detailed description

This study consists three phases: Prerandomization, Randomization (Core Study) and Extension study. The overall duration of treatment (Core and Extension) is approximately 104 weeks with the Core study being 26 weeks and the Extension study being 76 weeks. Approximately 45 participants 18 years of age and over who meet all the eligibility requirements will be randomized. No single platelet count should be greater than 35x10\^9/L (liter). Participants will be centrally stratified at randomization by splenectomy status, baseline platelet count, and use of concomitant ITP medication at baseline, and randomized to receive either double-blind avatrombopag or placebo in a 2:1 ratio. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag or placebo once daily. Participants will be allowed to have their dose titrated up (maximum dose 40 mg avatrombopag or matching placebo) or down (minimum dose 5 mg for avatrombopag or matching placebo) depending on their response to study drug. The goal of dose modification is to maintain the platelet count at levels greater than or equal to 50x10\^9/L and less than or equal to 150x10\^9/L, and to decrease the need for ITP-directed concomitant medications.

03

Conditions studied

  • Chronic Thrombocytopenia
  • Immune Thrombocytopenia

Keywords

  • Chronic Immune Thrombocytopenia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women greater than or equal to 18 years of age
  2. Participants diagnosed with cITP (greater than or equal to 12 months duration) according to the American Society for Hematology/British Committee for Standards in Hematology (ASH/BCSH) guidelines, and an average of 2 counts greater than 30x10\^9/L). The physical exam should not suggest any disease which may cause thrombocytopenia other than ITP
  3. Participants who previously received one or more ITP therapies (including, but not limited to , immunoglobulins, azathioprine, danazol, cyclophosphamide and/or rituximab).
  4. Participants must have had either initially responded (platelet count greater than 50x10\^9/L) to a previous ITP therapy or have had a bone marrow examination consistent with ITP within 3 years to rule out myelodysplastic syndrome (MDS) or other causes of thrombocytopenia
  5. /International Normalized Ratio (PT/INR) and activated partial thromboplastin time (aPTT) must have been within 80% to 120% of the normal range with no history of hypercoagulable state
  6. A complete blood count within the reference range (including white blood count [WBC] differential not indicative of a disorder other than ITP), with the following exceptions: : participants with hemoglobin levels between 10 g/dL (100 g/L) and the lower limit of normal (LLN) are eligible for inclusion, if anemia was clearly attributable to ITP (excessive blood loss); (ANC) greater than or equal to 1500/uL (1.5x10\^9/L) (elevated WBC/ANC due to corticosteroid treatment is acceptable)

Exclusion criteria

Exclusion Criteria:

  1. Participants with known secondary immune thrombocytopenia (e.g., with known Helicobacter pylori-induced ITP participants infected with known [HIV] or virus [HCV] or participants with known systemic lupus erythematosus). (Revised per Amendment 01)
  2. Participants with significant medical conditions that may impact on the safety of the participant or interpretation of the study results (e.g., acute hepatitis, active chronic hepatitis; lymphoproliferative disease; myeloproliferative disorders, leukemia)
  3. History of MDS
  4. History of gastric atrophy (added per Amendment 01)
  5. History of pernicious anemia or participants with vitamin B12 deficiency (defined as less than LLN) who have not had pernicious anemia excluded as a cause (added per Amendment 01)
  6. Any prior history of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis or pulmonary embolism), and more than two of the following risk factors: hormone replacement therapy, estrogen-containing hormone replacement or therapies, smoking, diabetes, hypercholesterolemia, medication for hypertension, cancer, hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency, etc.), or any other family history of arterial or venous thrombosis
  7. Participants with a history of significant cardiovascular disease (e.g., congestive heart failure [CHF] Grade III/IV, arrhythmia known to increase the risk of thromboembolic events [e.g., atrial fibrillation], participants with a corrected for heart rate of >450 msec, angina, coronary artery stent placement, angioplasty, coronary artery bypass grafting)
  8. Participants with a history of cirrhosis, portal hypertension, and chronic active hepatitis
  9. Participants with concurrent malignant disease
  10. Use of immunoglobulins (IVIg and anti-D) within 1 week of randomization
  11. Splenectomy or use of rituximab within 12 weeks of randomization
  12. Use of romiplostim or eltrombopag within 4 weeks of randomization
  13. Participants who are currently treated with or azathioprine but have not been receiving a stable dose for at least 4 weeks prior to randomization or have not completed these therapies more than 4 weeks prior to randomization
  14. Participants who are currently treated with MMF, CsA, or danazol but have not been receiving a stable dose for at least 12 weeks prior to randomization or have not completed these therapies more than 4 weeks prior to randomization
  15. Use of cyclophosphamide or vinca alkaloid regimens within 4 weeks of randomization
  16. Participants who are currently treated with PPIs or H2 antagonist therapy but have not been receiving a stable dose for at least 6 weeks prior to randomization or have not completed these therapies more than 2 weeks prior to randomization
  17. Fasting gastrin-17 blood levels exceeding the at Screening for participants not on PPIs or H2 antagonists (Revised per Amendment 01)
  18. Fasting gastrin-17 blood levels exceeding 1.5 times the upper limit of normal (ULN) at Screening for participants on PPIs or H2 antagonists (Added per Amendment 01)
  19. Blood creatinine exceeding ULN by more than 20% OR total albumin below the lower limit of normal (LLN) by 10%
  20. (ALT) OR aspartate aminotransferase (AST) levels exceeding 3 times the ULN or total exceeding 2 times the ULN
  21. Participants with a history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy.
  22. Participants with a history of ITP treatment with cytotoxic chemotherapy are still eligible for enrollment.
  23. Females who are pregnant (positive beta-human chorionic gonadotropin positive [B-hCG] test) or breastfeeding
  24. Participants with a known allergy to avatrombopag (E5501) or its
Terms in these criteria, in plain language(15)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
49 participants (actual)

Study arms

  • Active comparator
    Avatrombopag (Core Study)

    Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg, or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, one daily and allowed to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.

    Drug: Avatrombopag · Drug: Standard of care

  • Placebo comparator
    Placebo (Core Study)

    Placebo will be administered as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Placebo will be administered orally at a starting dose of 20 mg, once daily. Afterwards the dose can be titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on the participant's response to the study drug; placebo titration will be used to maintain the blind.

    Drug: Placebo · Drug: Standard of care

  • Experimental
    Avatrombopag (Open-Label Extension)

    Participants who meet all eligibility criteria requirements of extension phase and who discontinue the core study because of lack of treatment effect will continue into the extension phase. Avatrombopag will be administered to participants who enter extension phase, with a starting dose of 20 mg avatrombopag, once daily for 76 weeks and undergo dose titration.

    Drug: Avatrombopag · Drug: Standard of care

Interventions

  • Also known as: E5501, Avatrombopag maleate

  • DrugPlacebo
  • DrugStandard of care

    Permitted ITP concomitant background therapies are as follows: * Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization; * Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization; * Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization. At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen. Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.

06

What researchers measure

Primary outcomes

  1. Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period

    The cumulative number of weeks of platelet response is defined as the total numbers of weeks in which the platelet count is greater than or equal to 50 x 10\^ 9/L during 6 months of treatment of core study in the absence of rescue therapy.

    Time frame: Week 1 to Week 26

Secondary outcomes

  1. Number of Participants With a Reduction in Use of Concomitant Immune/Idiopathic Thrombocytopenic Purpura (ITP) Medication

    Only participants on concomitant ITP medications at baseline were included.

    Time frame: Week 1 through Week 26

  2. Number of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Day 8

    Participants with platelet response at Day 8 are defined as those who had a platelet count greater than or equal to 50 x 10\^9/L at day 8 in the absence of rescue therapy on or before Day 8.

    Time frame: Week 1 (Day 8)

07

Results

Posted Jan 5, 2018

Participant flow

Core Study
Participant flow — Core Study
MilestonePlacebo (Core Study)Avatrombopag (Core Study)Avatrombopag (Extension Phase)
Started17320
Completed1220
Not completed16100
Withdrew: Adverse event030
Withdrew: Lack of efficacy1570
Withdrew: Withdrawal of consent100
Extension Phase
Participant flow — Extension Phase
MilestonePlacebo (Core Study)Avatrombopag (Core Study)Avatrombopag (Extension Phase)
Started0039
Completed0029
Not completed0010
Withdrew: Adverse event003
Withdrew: Lost to follow-up001
Withdrew: Withdrawal by subject003
Withdrew: Lack of efficacy002
Withdrew: Other001

Outcome measures

PrimaryNumber of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period

The cumulative number of weeks of platelet response is defined as the total numbers of weeks in which the platelet count is greater than or equal to 50 x 10\^ 9/L during 6 months of treatment of core study in the absence of rescue therapy.

Time frame:
Week 1 to Week 26
Reported as:
Median · Weeks
Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period
WeeksPlacebo (Core Study)Avatrombopag (Core Study)
Number of Weeks With Platelet Count Greater Than or Equal to 50 x 10^9/L During 6-Month Treatment Period0 (0 to 2)12.4 (0 to 25)
Statistical analysis
  • Placebo (Core Study) vs Avatrombopag (Core Study) · Wilcoxon (Mann-Whitney) · p = <0.0001
SecondaryNumber of Participants With a Reduction in Use of Concomitant Immune/Idiopathic Thrombocytopenic Purpura (ITP) Medication

Only participants on concomitant ITP medications at baseline were included.

Time frame:
Week 1 through Week 26
Reported as:
Count of participants · Participants
Number of Participants With a Reduction in Use of Concomitant Immune/Idiopathic Thrombocytopenic Purpura (ITP) Medication
ParticipantsPlacebo (Core Study)Avatrombopag (Core Study)
Yes05
No710
SecondaryNumber of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Day 8

Participants with platelet response at Day 8 are defined as those who had a platelet count greater than or equal to 50 x 10\^9/L at day 8 in the absence of rescue therapy on or before Day 8.

Time frame:
Week 1 (Day 8)
Reported as:
Count of participants · Participants
Number of Participants With Platelet Count Greater Than or Equal to 50 x 10^9/L at Day 8
ParticipantsPlacebo (Core Study)Avatrombopag (Core Study)
Yes021
No1711

Adverse events

Collected over Core Study: up to 39 Weeks (including Screening, Titration, Treatment, Dose Taper, and Follow-up for those who did not enter the Extension Phase). Extension Phase: up to 104 weeks (including Conversion, Maintenance Period, Dose Taper, and Follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Placebo (Core Study)—1/17 (5.9%)10/17 (58.8%)
Avatrombopag (Core Study)—9/32 (28.1%)31/32 (96.9%)
Avatrombopag (Extension Phase)—15/47 (31.9%)45/47 (95.7%)
Most frequent serious events
Showing 10 of 25
Most frequent serious events
EventPlacebo (Core Study)Avatrombopag (Core Study)Avatrombopag (Extension Phase)
ThrombocytopeniaBlood and lymphatic system disorders0/171/323/47
VomitingGastrointestinal disorders0/172/322/47
HeadacheNervous system disorders0/172/322/47
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders1/170/320/47
Platelet count decreasedInvestigations0/171/322/47
Food poisoningGastrointestinal disorders0/171/321/47
Mouth haemorrhageGastrointestinal disorders0/171/321/47
NauseaGastrointestinal disorders0/171/321/47
PolyserositisGeneral disorders0/171/321/47
Urinary tract infectionInfections and infestations0/171/321/47
Most frequent other events
Showing 10 of 30
Most frequent other events
EventPlacebo (Core Study)Avatrombopag (Core Study)Avatrombopag (Extension Phase)
ContusionInjury, poisoning and procedural complications4/1710/3219/47
HeadacheNervous system disorders2/1712/3214/47
Upper respiratory tract infectionInfections and infestations1/176/3211/47
ThrombocytopeniaBlood and lymphatic system disorders0/172/329/47
EpistaxisRespiratory, thoracic and mediastinal disorders3/174/328/47
Gingival bleedingGastrointestinal disorders0/174/328/47
FatigueGeneral disorders1/174/327/47
PetechiaeSkin and subcutaneous tissue disorders1/174/327/47
PharyngitisInfections and infestations1/170/326/47
ArthralgiaMusculoskeletal and connective tissue disorders0/174/325/47

Baseline characteristics

Age, Continuous
Age, Continuous(Years)Placebo (Core Study)Avatrombopag (Core Study)Total
Geometric mean41.2 ± 14.746.4 ± 14.244.6 ± 14.44
Sex: Female, Male
Sex: Female, Male(Participants)Placebo (Core Study)Avatrombopag (Core Study)Total
Female82331
Male9918
08

Study locations

25 sites
  • Adelaide, Australia
  • Bedford Park, Australia
  • Antwerpen, Belgium
  • Plovdiv, Bulgaria
  • Sofia, Bulgaria
  • Brno, Czechia
  • Hradec Kralove, Czechia
  • Praha, Czechia
  • Rotterdam, Netherlands
  • Christchurch, New Zealand
  • Palmerston North, New Zealand
  • Bialystok, Poland
  • Chorzow, Poland
  • Gdansk, Poland
  • Krakow, Poland
  • Lodz, Poland
  • Wroclaw, Poland
  • Singapore, Singapore
  • Bratislava, Slovakia
  • Johannesburg, South Africa
  • Dnipropetrovsk, Ukraine
  • Donetsk, Ukraine
  • Ivano-Frankivsk, Ukraine
  • Kyiv, Ukraine
  • Lviv, Ukraine
09

References and documents

Publications

  • Jurczak W, Chojnowski K, Mayer J, Krawczyk K, Jamieson BD, Tian W, Allen LF. Phase 3 randomised study of avatrombopag, a novel thrombopoietin receptor agonist for the treatment of chronic immune thrombocytopenia. Br J Haematol. 2018 Nov;183(3):479-490. doi: 10.1111/bjh.15573. Epub 2018 Sep 7. PubMed 30191972 ↗
10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2012 to primary completion in Nov 2013, 21 months.

Results were first posted in Jan 2018, 4 years 2 months after primary completion. A results delay was requested in Jun 2015.

Of 41 industry-sponsored phase 3 interventional studies under Purpura, Thrombocytopenic, Idiopathic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 44. This study's 21 months is below that.

Counting every sponsor, half of 57 studies reached it within 28 months; a quarter within 22 and three quarters within 49.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 19, 2011
First posted
Sep 22, 2011
StartActual
Feb 16, 2012
Primary completionActual
Nov 2013
CompletionActual
Mar 2014
Results delay requested
Jun 29, 2015
Results first posted
Jan 5, 2018
Last update
Feb 5, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT01438840
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Sep 22, 2011
Start date
Feb 16, 2012
Primary completion
Nov 2013
Completion
Mar 2014
Results posted
Jan 5, 2018
Last update
Feb 5, 2018

Study contacts

Joe McIntosh
study director · Eisai Inc.

Oversight

Data monitoring committee
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion